A Look At ORIC Pharmaceuticals (ORIC) Valuation After Promising Rinzimetostat Phase 1b Prostate Cancer Data

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Immunovant eye drug flunks Phase 3 studies; Beam sickle cell data published in NEJM

ORIC Pharmaceuticals (ORIC) Is Down 36.1% After Advancing Lower-Toxicity Prostate Cancer Drug to Phase 3

Oric Pharma Misses The 'Best-In-Class' Boat Vs. Pfizer — And Plunges

Oric Shares Fall 40% as Cancer-Drug Data Falls Short of Expectations

Wall Street Set to Open Higher as Trump Says US Will Consider Ceasefire if Hormuz Strait Opened

Oric Pharmaceuticals Unveils Rinzimetostat Phase Ib Data, Sets Stage for Phase III Himalayas-1 Trial

ORIC® Pharmaceuticals Reports Selection of Rinzimetostat RP3D in Combination with Darolutamide for Himalayas-1 Phase 3 Global Study with Dose Optimization Data Supporting Its Potential Best-in-Disease Profile

ORIC® Pharmaceuticals to Report Combination Dose Optimization Data From Phase 1b Trial of Rinzimetostat in Patients with mCRPC